Apigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies
Hatice Terzi, Şeyma Taştemur, Ayşegül Öztürk, Neslihan Başgöz Karaguş, Mustafa Eymen Kontaş, Onur Mahmutoğlu, Ali Güngör, Mehmet Şencan · 2026
Read Apigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies by Hatice Terzi, Şeyma Taştemur, Ayşegül Öztürk, Neslihan Başgöz Karaguş, Mustafa Eymen Kontaş, Onur Mahmutoğlu, Ali Güngör, Mehmet Şencan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13256365.txt.
Description
Hatice Terzi and colleagues report a 2026 cell study of apigenin, a plant flavonoid found in foods like parsley and chamomile, against blood cancers. The team treated a chronic myeloid leukemia line and a B-cell lymphoma line, checking survival and signaling, with ordinary mouse fibroblasts as a selectivity comparison.
Apigenin reduced cancer cell survival in proportion to dose and froze cells in the S phase of the cycle. It dampened four growth and survival signals, EGFR, MAPK, PI3K, and NF-κB, while raising two executioner enzymes of cell death. The fibroblasts tolerated the compound better, losing viability only at top doses. The authors argue that hitting two major pathways at once, EGFR/MAPK and PI3K/Akt, makes apigenin interesting, and they recommend animal studies before any clinical talk.
Catalog record
| CREATOR | Hatice Terzi, Şeyma Taştemur, Ayşegül Öztürk, Neslihan Başgöz Karaguş, Mustafa Eymen Kontaş, Onur Mahmutoğlu, Ali Güngör, Mehmet Şencan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |